P/E ratio for Quotient (QTNT)
P/E ratio as of April 2024 (TTM): -0.0903
According to Quotient's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0902559. At the end of 2020 the company had a P/E ratio of -4.74.
P/E ratio history for Quotient from 2014 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2020 | -4.74 | -22.8% |
| 2019 | -6.14 | 98.5% |
| 2018 | -3.09 | 42.99% |
| 2017 | -2.16 | 21.92% |
| 2016 | -1.77 | -83.71% |
| 2015 | -10.9 | 817.13% |
| 2014 | -1.19 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Atossa Therapeutics ATOS | -5.96 | 6,503.45% | 🇺🇸 USA |
 Chembio Diagnostics CEMI | -0.3792 | 320.10% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | -0.3475 | 285.04% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.